1019-206 Reduced adverse event rates after transcatheter closure of patent foramen ovale when using the amplatzer-PFO™ compared to the CardioSeal™ device

MLA

Robert R. Pearson, et al. “1019-206 Reduced Adverse Event Rates after Transcatheter Closure of Patent Foramen Ovale When Using the Amplatzer-PFO™ Compared to the CardioSeal™ Device.” Journal of the American College of Cardiology, no. 5, p. A377. EBSCOhost, https://doi.org/10.1016/S0735-1097(04)91593-8. Accessed 15 Feb. 2025.

APA

Robert R. Pearson, Peter J. Casterella, Sherman G. Sorensen, Joseph B. Muhlestein, Jeffrey L. Anderson, Benjamin D. Horne, Donald L Lappe, & Laurie Raleigh. (n.d.). 1019-206 Reduced adverse event rates after transcatheter closure of patent foramen ovale when using the amplatzer-PFO™ compared to the CardioSeal™ device. Journal of the American College of Cardiology, 5, A377. https://doi.org/10.1016/S0735-1097(04)91593-8

Chicago

Robert R. Pearson, Peter J. Casterella, Sherman G. Sorensen, Joseph B. Muhlestein, Jeffrey L. Anderson, Benjamin D. Horne, Donald L Lappe, and Laurie Raleigh. 2025. “1019-206 Reduced Adverse Event Rates after Transcatheter Closure of Patent Foramen Ovale When Using the Amplatzer-PFO™ Compared to the CardioSeal™ Device.” Journal of the American College of Cardiology, no. 5: A377. Accessed February 15. doi:10.1016/S0735-1097(04)91593-8.